Advanced in Primitive Neuroectodermal Tumor (PNET)

Dr. Christina I. Tsien

Radiation Oncology

5255 Loughboro Rd Nw Bldg A1,

Washington, DC

Clinical Trials:Currently Recruiting for 1 Trial

Advanced in Primitive Neuroectodermal Tumor (PNET)

5255 Loughboro Rd Nw Bldg A1,

Washington, DC

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christina Tsien is a Radiation Oncologist in Washington, Washington, D.c.. Dr. Tsien is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Glioma, Gliomatosis Cerebri, Glioblastoma, Gastrostomy, and Gamma Knife Radiosurgery.

Her clinical research consists of co-authoring 105 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Radiation Oncology

Licenses

Radiology in MO

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Humana

HMO
INDEMNITY
POS
PPO

Locations

5255 Loughboro Rd Nw Bldg A1, Washington, DC 20016

Call: 314-747-7236

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Enrollment Status: Recruiting

Publish Date: September 08, 2025

Intervention Type: Other, Procedure, Radiation

Study Phase: Phase 3

Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Enrollment Status: Active_not_recruiting

Publish Date: August 07, 2025

Intervention Type: Drug, Radiation

Study Drugs: Epacadostat, Bevacizumab

Study Phase: Phase 2

A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas

Enrollment Status: Active_not_recruiting

Publish Date: July 11, 2025

Intervention Type: Other, Procedure, Drug, Radiation

Study Drug: Temozolomide

Study Phase: Phase 2

Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide

Enrollment Status: Active_not_recruiting

Publish Date: July 02, 2025

Intervention Type: Procedure, Drug, Radiation

Study Drugs: rhIL-7-hyFc, Temozolomide

Study Phase: Phase 1/Phase 2

A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Enrollment Status: Completed

Publish Date: April 10, 2025

Intervention Type: Drug, Procedure, Radiation

Study Drugs: Disulfiram, Copper Gluconate, Temozolomide

Study Phase: Phase 1/Phase 2

A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Enrollment Status: Active_not_recruiting

Publish Date: January 10, 2025

Intervention Type: Device, Biological, Drug

Study Drugs: Personalized neoantigen DNA vaccine, Plasmid encoded IL-12

Study Phase: Phase 1

A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma

Enrollment Status: Terminated

Publish Date: June 15, 2023

Intervention Type: Radiation, Drug, Procedure

Study Drug: Avelumab

Study Phase: Phase 1

A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

Enrollment Status: Completed

Publish Date: May 11, 2023

Intervention Type: Drug, Radiation

Study Drugs: Temozolomide, Depatuxizumab

Study Phase: Phase 3

Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases

Enrollment Status: Terminated

Publish Date: March 23, 2023

Intervention Type: Drug, Other

Study Phase: Phase 2

A Phase 1 Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM)

Enrollment Status: Completed

Publish Date: November 03, 2021

Intervention Type: Drug

Study Drug: RRx-001

Study Phase: Phase 1

A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Enrollment Status: Terminated

Publish Date: October 27, 2021

Intervention Type: Procedure, Biological

Study Phase: Phase 1

A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme

Enrollment Status: Completed

Publish Date: August 27, 2021

Intervention Type: Device, Drug, Other

Study Phase: Phase 1

A Pharmacodynamic Study of Proteasome Inhibition by Disulfiram in Patients With Glioblastoma

Enrollment Status: Completed

Publish Date: July 20, 2018

Intervention Type: Drug, Dietary supplement

Study Phase: Early Phase 1

A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma

Enrollment Status: Terminated

Publish Date: November 17, 2017

Intervention Type: Drug, Biological

Study Phase: Phase 1

View 13 Less Clinical Trials

105 Total Publications

Radiation Therapy for WHO Grade 4 Adult-Type Diffuse Glioma: An ASTRO Clinical Practice Guideline.

Journal: Practical radiation oncology

Published: May 28, 2025

View All 105 Publications

Similar Doctors

Distinguished in Primitive Neuroectodermal Tumor (PNET)

Dr. Lawrence R. Kleinberg

Radiation Oncology

Distinguished in Primitive Neuroectodermal Tumor (PNET)

Dr. Lawrence R. Kleinberg

Radiation Oncology

Johns Hopkins University

600 N Wolf St,

Baltimore, MD

(36.5 miles away)

410-955-5000

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Lawrence Kleinberg is a Radiation Oncologist in Baltimore, Maryland. Dr. Kleinberg is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Hepato-Pancreato-Biliary Surgery, and Gamma Knife Radiosurgery. Dr. Kleinberg is currently accepting new patients.

Distinguished in Primitive Neuroectodermal Tumor (PNET)

Dr. Kristin J. Redmond

Radiation Oncology

Distinguished in Primitive Neuroectodermal Tumor (PNET)

Dr. Kristin J. Redmond

Radiation Oncology

Johns Hopkins University

5215 Loughboro Rd Nw, Sibley Memorial Hospital,

Washington, DC

(0.9 miles away)

202-537-4000

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Kristin Redmond is a Radiation Oncologist in Washington, Washington, D.c.. Dr. Redmond is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Chordoma, Brain Tumor, Astrocytoma, and Metastatic Brain Tumor. Dr. Redmond is currently accepting new patients.

Distinguished in Primitive Neuroectodermal Tumor (PNET)

Dr. Michael J. Eblan

Radiation Oncology

Distinguished in Primitive Neuroectodermal Tumor (PNET)

Dr. Michael J. Eblan

Radiation Oncology

Radiation Oncology Associates PC

44035 Riverside Pkwy, Suite 100,

Leesburg, VA

(22.9 miles away)

703-858-8850

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Michael Eblan is a Radiation Oncologist in Leesburg, Virginia. Dr. Eblan is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Prostate Cancer, and Familial Prostate Cancer. Dr. Eblan is currently accepting new patients.

VIEW MORE PRIMITIVE NEUROECTODERMAL TUMOR (PNET) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tsien's expertise for a condition

ConditionClose